US Pharma MarketingAlumis pulls back from would-be rival to Amgen’s Tepezza after assessing prospects
Alumis pulls back from would-be rival to Amgen’s Tepezza after assessing prospects is a pharma and life sciences industry update from FierceBiotech. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
Alumis is exploring strategic alternatives for its would-be rival to Amgen’s Tepezza, choosing to punt the program rather than pursue the phase 3 program envisaged before it acquired the asset.
Source: FierceBiotech